SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 open label multicentre study of SHR9549 administered orally in patients
with advanced estrogen receptor (ER) positive human epidermal receptor 2 (HER2) negative
breast cancer. The study design allows an escalation of dose with intensive safety monitoring
to ensure the safety of patients. The study will determine the maximum tolerated dose(MTD).
In addition, expansion cohort(s) at potential therapeutic dose(s) in patients will be
enrolled to further determine the safety, tolerability, pharmacokinetics and biological
activity of SHR9549.